

## Supplementary (online only) materials

### Supplementary Table 1 Correlation analysis performed

---

#### Variables

---

#### **Changes in DAS28 up to week 12 vs week 24**

Changes in GLOESS (22 paired joints, reduced 9 paired joint set) from baseline up to week 12 vs baseline to week 24

#### **Changes in GLOESS (MCPs 2–5, 22 paired joints, reduced 9 paired joint set) from baseline up to week 12 and lower levels of synovitis\* at week 24**

Changes in GLOESS at week 1 and changes in GLOESS during the entire treatment period (baseline to week 24)

#### **Changes in DAS28 and changes in GLOESS (MCPs 2–5, 22 paired joints, reduced 9 paired joint set, 28 joints<sup>†</sup>) or component scores (SH, PD, JE) from baseline**

GLOESS (MCPs 2–5) or component scores (SH, PD, JE) vs SJC

#### **GLOESS (MCPs 2–5) or component scores (SH, PD, JE) vs TJC**

#### **GLOESS (MCPs 2–5) or component scores (SH, PD, JE) vs SJC + TJC combined**

#### **Changes in GLOESS (MCPs 2–5, 22 paired joints, reduced 9 paired joint set) week or components (SH, PD, JE) up to week 4 vs change in the sum of swollen joints (MCPs 2–5, 22 paired joints, reduced 9 paired joint set) at weeks 12 and 24**

---

\*Defined by a GLOESS at week 24 that was less than the median GLOESS at that time point. <sup>†</sup>The 28 joints assessed for tenderness and swelling as part of the DAS28. DAS28, Disease Activity Score 28; GLOESS, Global OMERACT-EULAR Synovitis Score; JE, joint effusion; MCPs, metacarpophalangeal joints; PD, power Doppler assessed synovial vascularization; SH, hypoechoic synovial hyperplasia; SJC, swollen joint count; TJC, tender joint count.

**Supplementary Table 2** Correlation between changes in GLOESS up to week 12 and achieving lower levels of synovitis at week 24 (defined as having a GLOESS at week 24 that is less than the median value at that time point)

	<b>Spearman's correlation coefficient</b>		
	<b>MCPs (2–5)</b>	<b>22 paired joint set</b>	<b>Reduced 9 paired joint set</b>
Baseline to week 1	–0.36 (–0.53, –0.14)	–0.01 (–0.23, 0.21)	0.07 (–0.16, 0.30)
Baseline to week 2	–0.20 (–0.39, 0.02)	–0.02 (–0.23, 0.19)	–0.01 (–0.23, 0.20)
Baseline to week 4	–0.44 (–0.59, –0.24)	–0.19 (–0.39, 0.03)	–0.08 (–0.30, 0.14)
Baseline to week 8	–0.31 (–0.49, –0.10)	–0.15 (–0.36, 0.07)	0.09 (–0.14, 0.31)
Baseline to week 12	–0.55 (–0.68, –0.37)	–0.30 (–0.49, –0.09)	–0.16 (–0.37, 0.06)

CI, confidence interval; GLOESS, Global OMERACT-EULAR Synovitis Score; MCPs, metacarpophalangeal joints.

**Supplementary Table 3** Standardized response means for changes in DAS28 and GLOESS using the MCP 2–5, 22 paired, and reduced 9 paired joint sets

<b>Measure</b>	<b>Time point</b>	<b>n</b>	<b>Mean change from baseline</b>	<b>SE</b>	<b>SD</b>	<b>SRM*</b>
DAS28	Week 1	91	−0.55	0.078	0.743	−0.734
	Week12	103	−1.77	0.113	1.149	−1.542
	Week 24	103	−2.13	0.136	1.379	−1.541
GLOESS (MCPs 2–5)	Week 1	86	−0.70	0.282	2.615	−0.268
	Week12	95	−3.80	0.454	4.425	−0.859
	Week 24	95	−4.80	0.473	4.610	−1.041
GLOESS (22 paired joints)	Week 1	87	−1.70	0.852	7.947	−0.214
	Week12	95	−11.70	1.39	13.548	−0.864
	Week 24	95	−15.70	1.65	16.082	−0.976
GLOESS (reduced 9 paired joint set)	Week 1	81	−0.60	0.362	3.258	−0.184
	Week12	91	−5.30	0.583	5.561	−0.953
	Week 24	91	−6.40	0.725	6.916	−0.925

\*SRM was calculated by dividing the mean change from baseline by the SD of the change. DAS28, Disease Activity Score 28; GLOESS, Global OMERACT-EULAR Synovitis Score; MCP, metacarpophalangeal; SD, standard deviation; SE, standard error; SRM, standardized response mean.